RESULTS Both DDP and VP16 obviously inhibited the lung cancer cell growth with dose and time dependent.
结果不同浓度VP16和DDP对肺癌细胞生长均有明显的抑制作用，并有浓度和时间的依赖性。
These compounds were assayed for inhibitory activity against A549 lung cancer cell growth, and the inhibitory effects on the cell viability were dose-dependent.
所得化合物均具有抑制A549肺癌细胞生长的活性，其抑制效果具有浓度依赖性。
Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
中国的非小细胞肺癌病人中吉非替尼敏感的表皮生长因子受体酪氨酸激酶区域的突变。
Chemotherapy given in combination with ligands for the peroxisome proliferator-activated receptor - (PPAR) synergistically inhibits the growth of lung and ovarian cancer cell lines.
化疗药物联合过氧化物酶体增殖物激活受体(PPAR)的配体能够协同抑制肺细胞癌及卵巢癌细胞。
Clinicopathologic Significance of the Mutations of the Epidermal Growth Factor Receptor Gene in Patients with Non-Small Cell Lung Cancer.
非小细胞肺癌病人的表皮生长因子受体基因突变的临床病理意义。
Objective to investigate the regulatory effects of tuberculin on growth and apoptosis of liver cancer and lung cancer cell lines.
目的探讨结核菌素对肝癌和肺癌肿瘤细胞生长和凋亡的调控作用。
ConclusionThe lung cancer associated antigen N35 might be an important tumor associated antigen and related with the proliferation of cancer cells as a role of tumor cell growth regulator.
结论肺癌相关抗原n 35是一种重要的肿瘤相关抗原，其功能很可能与肿瘤细胞无限制增殖活动有关。麦芽凝集素亲和层析法是纯化肺癌相关蛋白n 35简便有效的途径。
This is the first FDA-approved, blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients.
这是FDA批准的首个能够检测非小细胞肺癌患者表皮生长因子受体(EGFR)基因突变的、以血液为基础的基因检测试剂盒。
A549 lung cancer cell was cultivated by the magnetized water, and the growth curve was drawn by MTT colorimetry.
然后将磁化水应用于A549肺癌细胞的体外培养，观察a 549肺癌细胞的生长情况，用MTT比色法绘制细胞生长曲线。
Objective To evaluate the effect of vascular endothelia1 growth factor(VEGF)on the hematogenous metastasis of non small cell lung cancer (NSCLC).
目的探讨血管内皮生长因子（VEGF）含量对非小细胞肺癌（NSCLC）血道转移的影响。
Objective to evaluate the clinical significance of epidermal growth factor receptor EGFR mutations in the treatment of non-small cell lung cancer NSCLC.
目的探讨外周血表皮生长因子受体(EGFR)基因突变在非小细胞肺癌(NSCLC)吉非替尼治疗适宜患者筛选中的价值。
ObjectiveTo explore the influence of the expression of insulin-like growth factor-1 receptor(IGF-1R)in end-stage non-small cell lung cancer.
目的明确肿瘤组织胰岛素样生长因子-1受体（IGF-1R）表达对晚期非小细胞肺癌化疗疗效及生存的影响。
Comparison of the growth and proliferation of small cell lung cancer is very slow.
的成长和比较小细胞肺癌癌细胞的扩散速度很慢。
Comparison of the growth and proliferation of small cell lung cancer is very slow.
的成长和比较小细胞肺癌癌细胞的扩散速度很慢。
应用推荐